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Fluticasone furoate/ﬂuticasone propionate – different drugs
with different propertiescrj_244 183..184
The similarity in the names of the recently introduced
intranasal glucocorticoid ﬂuticasone furoate (FF;
Veramyst®, GlaxoSmithKline/Avamys®, GlaxoSmith-
Kline UK, Uxbridge, UK) and the earlier ﬂuticasone
propionate (FP; Flonase®/Flixonase®, GlaxoSmith-
Kline) has led many to assume that the two com-
pounds have the same active principle (ﬂuticasone)
(e.g. 1, 2). This has been compounded by FP com-
monly, and incorrectly, being abbreviated to ﬂutica-
sone. The purpose of this letter is to highlight that FF
and FP are completely different drugs with FF showing
distinct and superior properties (3),and hence prevent
any misprescription of these drugs in the future.
This confusion clearly stems from the unusual
assigned glucocorticoid nomenclature which splits
these molecules into the steroidal backbone (ﬂutica-
sone) and the ester substituent (furoate/propionate).
This naming convention does suggest that these
derivatives could be ester prodrugs of ﬂuticasone. In
fact, a number of topical glucocorticoid esters are
indeed ester prodrugs releasing the active parent
glucocorticoid in the body. However, ﬂuticasone 17a
esters are remarkably stable and remain attached to the
ﬂuticasone backbone even during metabolism. Their
pharmacologicalactivityismediatedbytheentiremol-
ecule (backbone + ester) and they share no common
metabolites (Fig. 1) – neither FF nor FP is metabolised
to ﬂuticasone.FF and FP are therefore structurally dis-
tinct drug substances with distinct properties.
The furoate and propionate moieties are far from
inert appendages but serve to signiﬁcantly enhance the
glucocorticoid activity of ﬂuticasone, which has never
itself been developed. Key interactions of FF with the
glucocorticoid receptor have been elucidated by X-ray
crystallography which shows the ester derived from
2-furoic acid occupying a discrete pocket on the recep-
tor much more completely than does the smaller pro-
pionate ester of FP (4).The resulting enhanced afﬁnity
of FF for the target receptor is reﬂected in the lower
daily dose of Veramyst (110 mg) compared with
Flonase (200 mg).
The ester group also contributes to the physico-
chemical characteristics of the molecule which impact
on solubility,dissolution rate,tissue afﬁnity,and hence
pharmacokinetic and pharmacodynamic properties.
Thus,theesterderivedfrom2-furoicacidinFFconfers
higher afﬁnity for both nasal and lung tissue compared
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Figure 1. Structures of ﬂuticasone
furoate and ﬂuticasone propionate and
their major metabolites.
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shown that this translates to enhanced lung residency
and once-daily efﬁcacy in asthma (7, 8). There is
already some evidence that the characteristics of FF
may result in superior symptom reduction compared
with FP (9, 10) or similar improvements in symptoms
at less frequent dosing schedules (11), which could
result in reduced health-care costs/concomitant medi-
cation use (12); however, prospective, randomised,
head-to-head studies are required to provide a deﬁni-
tive answer. With new inhaled products containing FF
in Phase III trials (Relovair®, GlaxoSmithKline) it is
important for prescribers to understand that this is a
novel glucocorticoid, not to be confused with FP.
Moreover, the practice of abbreviating FP and FF to
ﬂuticasone should be discouraged.
Keith Biggadike
Allergic Inﬂammation DPU, Respiratory CEDD
GlaxoSmithKline Medicines Research Centre
Stevenage, Hertfordshire, UK
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